Treatment Compass

How Long Does Suboxone Stay in Your System?

Last updated

Buprenorphine, the active ingredient in Suboxone, has a mean elimination half-life of 24 to 42 hours according to its FDA label, which puts the practical end of elimination around five to nine days after the last dose. A urine test picks it up for roughly a week after daily treatment and for about three days after a single dose; blood and saliva see it for a day or two; hair records it for months. Two things people conflate are worth separating: the drug is detectable for much longer than it keeps working, and the receptor blockade that protects against overdose has largely faded within two to three days, long before a urine test turns negative. Standard federal and DOT drug panels do not test for buprenorphine at all; it only appears on tests that include a specific buprenorphine assay.

The short version

  1. Half-life is 24 to 42 hours — the FDA label figure: the 2 to 4 hours printed on some test-kit inserts is an outdated distribution-phase number
  2. Urine: about a week after daily treatment — about three days after a single dose by mass spectrometry, and the metabolite norbuprenorphine outlasts the drug itself
  3. The blockade fades in two to three days — receptor occupancy fell from about 70% to 18% over 76 hours in a PET study: the safety window closes before the test window does
  4. Standard panels do not look for it — the federal five-panel and DOT tests contain no buprenorphine assay; a specific test is needed, and instant cups that include one cut off at 10 ng/mL
Three figures: buprenorphine elimination half-life 24 to 42 hours, urine positive about one week after daily treatment
The drug outlasts its effect. The middle number is the one a test sees; the last one is the one that decides safety.
Three-column diagram of buprenorphine, naloxone and the metabolite norbuprenorphine with the half-life and testing relevance
Which of the three molecules a laboratory measures decides the detection window, and it is usually the metabolite that is found last.
Bar chart of elimination half-lives in hours: naloxone 2 to 12, buprenorphine 24 to 42
The naloxone component is gone within a day; the buprenorphine is what remains, and what every test is built to find.
Bar chart showing that five half-lives take 5 days at a 24-hour half-life and 8.75 days at a 42-hour half-life
This is where the widely quoted five-to-eight-day figure comes from: the label range multiplied by the pharmacology convention for elimination.
Bar chart of detection windows in days by test type: blood 1 to 2, saliva up to 2, urine 3 to 4 after a single dose
The matrix matters more than the dose. Hair is a history, urine is the past week, blood and saliva are the past day or two.

What treatment programmes actually test for, from the federal directory

Our analysis

People ask which kind of test they will face. Nobody publishes that, so we counted it from the SAMHSA treatment locator: 10,233 facilities after deduplication, each listing the testing it performs.

90.4%
of facilities perform drug or alcohol urine screening
9,250 of 10,233 — urine is the default nearly everywhere
97.6%
of buprenorphine programmes test urine
5,910 of the 6,058 facilities offering buprenorphine; only 138 list neither urine nor oral-fluid testing
49.0%
also use oral-fluid (saliva) testing
and the spread is wide: 70.9% of New York facilities against 31.3% in Missouri

How we got this: we pulled the full public listing from SAMHSA’s FindTreatment.gov on , removed duplicate entries by name, street and ZIP, and counted how many of the 10,233 remaining facilities report each service. SAMHSA publishes the directory; it does not publish these proportions — see how the count is made. Repeat the pull and you will get the same numbers, give or take facilities that opened or closed since.

What these numbers cannot tell you: they are self-reported by facilities, they describe availability rather than quality, and a national proportion says nothing about what is open near you this week. Use them to know what to ask for, not to decide where to go.

Two clocks: how long it is detectable, and how long it works

Most answers to this question run the two together. One clock is elimination: how long buprenorphine and its metabolites remain in your body at a level a laboratory can measure. The other is effect: how long the medication keeps opioid receptors occupied enough to hold off withdrawal and blunt other opioids. They run at very different speeds, and the gap between them is where the real risk sits.

Why the numbers online disagree

Look at the package insert for a common instant urine test cup and you will find buprenorphine described as having a plasma half-life of two to four hours and a urine detection window of about three days. Look at the FDA label for Suboxone film and the mean elimination half-life is 24 to 42 hours. Both are printed by serious organisations. The insert figure is an old distribution-phase number — how quickly the drug leaves the blood for tissue — copied forward from early studies, while the label figure describes the slower terminal elimination that actually decides how long you test positive. When two pages give you numbers that differ by a factor of ten, this is usually why.

What this page can answer, and what only a lab can

Published ranges are populations, not people. The same dose leaves one person a day earlier than another, and the cutoff the laboratory uses moves the answer more than most physiological differences do. This page gives you the ranges from primary sources, the mechanisms that shift them, and the questions to ask about the specific test you are facing. It cannot tell you the day your own sample turns negative, and nobody honest can.

What is in Suboxone, and what a test is actually looking for

Suboxone contains two drugs, and the body makes a third from one of them. Which of the three a test measures decides the detection window, and this is the detail that the shortest answers leave out.

Buprenorphine

The active ingredient: a partial opioid agonist that occupies the mu-opioid receptor, relieves withdrawal and craving, and has a ceiling on its own opioid effect. It is about 96% bound to plasma proteins and distributes widely into tissue, which is one reason its elimination is slow. Sublingual absorption is what makes the film work; swallowed buprenorphine is largely destroyed on its first pass through the liver, which is why the label says not to chew or swallow it.

Naloxone

Added to discourage injection. Taken as intended under the tongue, very little is absorbed, and what does get in is gone quickly: the label gives naloxone a mean elimination half-life of two to twelve hours. Routine drug tests do not look for it. Some treatment-programme panels do, for a reason covered further down — its presence in urine distinguishes Suboxone from buprenorphine-only products.

Norbuprenorphine, the metabolite that outlasts the drug

The liver converts buprenorphine to norbuprenorphine, mainly through the enzyme CYP3A4, and both are then conjugated and excreted, most of it in faeces and roughly 10 to 30% in urine. Laboratory confirmation tests measure the parent drug and the metabolite separately. In the controlled single-dose study described below, buprenorphine itself had cleared from most volunteers by four days while every sample was still positive for norbuprenorphine. When a laboratory reports you positive after the drug itself is gone, the metabolite is what it found.

The half-life, and what it does and does not tell you

Half-life is the time for the concentration in blood to fall by half. It is the single number most pages quote, and it is genuinely useful, provided you know why it is a range and what it leaves out.

24 to 42 hours, and why that is a range rather than a number

The Suboxone label reports a mean elimination half-life from plasma of 24 to 42 hours for buprenorphine across the studies performed with the film. A 2005 review of buprenorphine pharmacokinetics found reported mean values ranging from 3 to 44 hours depending on how long each study kept sampling and how sensitive its assay was: short studies stop measuring while the drug is still leaving the blood for tissue and catch the fast phase, long ones catch the slow terminal phase. When you read a page that says the half-life is 37 hours, or 24, or 42, all of them are quoting real studies. The terminal figure is the one that matters for a drug test.

Five half-lives is the rule of thumb, and it gives roughly a week

A drug is conventionally considered eliminated after about five half-lives, when under 3% of the peak remains. At 24 hours that is five days; at 42 hours it is nearly nine. This is where the widely repeated five-to-eight-day figure comes from, and it lines up with what urine testing actually finds after daily dosing. It is a rule about concentration in blood, not about any particular test, and a sensitive urine test can keep finding the metabolite after the parent drug has fallen below this line.

What a half-life calculator cannot do

Online calculators multiply a dose by a fixed half-life and draw a curve. The curve is smooth; people are not. The published variation between individuals is large enough that two people on the same 16 mg dose can be a day or two apart in reaching any given concentration, and the calculator has no way to know your liver function, your other medicines or how much drug has accumulated in tissue over months of treatment. Treat the curve as a shape, not a schedule.

Dose changes the amount, not the clock

People search for how long 2 mg, 8 mg or 16 mg stays in the system: the half-life of a Suboxone 2mg, 4mg, 8mg or 16mg film or tablet (pill) is the same 24 to 42 hours, or half a film, or a quarter. A larger dose does not change the half-life; it starts the curve higher, so it takes longer to fall below a laboratory cutoff. The bigger difference is not between 8 mg and 16 mg on one day but between one dose and daily dosing for months: with a half-life longer than the dosing interval, the drug accumulates in tissue until intake and elimination balance, and that reservoir is what takes about a week to drain. A single small dose taken once clears in days; a maintenance dose taken every day for a year is a different starting point.

Detection windows by type of test

The matrix being tested matters more than almost anything else. A widely cited review of detection times across drug classes gives the general order — hair longest, then urine, then sweat, oral fluid and blood, and the buprenorphine-specific studies fit that pattern.

Urine

The standard matrix: a UDS, or urine drug screen, and the one nearly every treatment programme uses. After daily treatment, expect buprenorphine and norbuprenorphine to be detectable for about a week, occasionally longer, depending on the cutoff. After a single dose, a mass-spectrometry method found the parent drug for a mean of 76 hours, with a range of 23 to 96 hours, and the metabolite in every sample at 96 hours, the last time point measured. Two things move that window: the cutoff, since immunoassay screens at 5 or 10 ng/mL see far less than a confirmation method at 0.5 ng/mL, and the concentration of the urine itself.

Blood and plasma

Shortest window and least used outside hospitals and post-mortem work. Across drug classes, blood detects for a day or two at low nanogram levels. In a controlled study of very low sublingual doses of 0.2 and 0.4 mg, buprenorphine was no longer quantifiable in blood at six and a half hours; a treatment dose forty times larger is quantifiable considerably longer, but blood still turns negative well before urine does. A blood test is chosen when someone needs to know about recent impairment, not about use last week.

Saliva and mouth-swab tests

Oral fluid tracks blood more closely than urine does, and across drugs the general window is about five to 48 hours. Buprenorphine has a wrinkle: it is dosed in the mouth. A study that sampled oral fluid alongside plasma found the oral-fluid-to-plasma ratio fell the longer after the dose the sample was taken, consistent with residual drug in the mouth early on. In practice a mouth swab shortly after dosing reads very high, and a swab days later reads low or negative. Roughly half of US treatment facilities list oral-fluid testing, almost always alongside urine rather than instead of it.

Hair

Hair stores drug as it grows, at about a centimetre a month, and is used for a history rather than a recent-use question. In a controlled study, people who took 8 mg daily for up to 180 days showed buprenorphine and norbuprenorphine concentrated in exactly the hair segments corresponding to their treatment period, and the metabolite was usually present at higher levels than the drug. A later study of 79 patients found that between-person variation was too large to infer someone's dose from their hair, though changes within one person's own hair tracked their dose changes well. A standard 3 cm sample covers roughly three months.

Sweat

Sweat patches worn for a week or more are used in some monitoring programmes. In the one buprenorphine study that collected them, drug was found in only four of 25 patches and at low concentrations. It is a niche method for this medication and not one you are likely to encounter.

One dose versus daily treatment

The most searched variants of this question — after one-time use, after a small piece, after years of daily dosing — have genuinely different answers, and the single-dose research is more precise than most pages let on.

After a single dose

Eighteen volunteers took one sublingual dose of 0.4 mg, a fraction of a treatment dose, and gave urine samples for four days. On the immunoassay screen, the mean period of continuous positive results was nine hours, with a range of four to 24. On the mass-spectrometry method with a 0.5 ng/mL cutoff, it was 76 hours for buprenorphine, and norbuprenorphine was still present in every sample at 96 hours. The ratio of metabolite to parent drug crossed one at about seven hours, which the authors proposed as a way to estimate when a dose was taken. Scale that up to a 2 or 8 mg dose and the parent drug is findable for several days; scale it to a screening cup and it may be findable for barely a day.

After months of daily treatment

Daily dosing builds a reservoir in tissue that a single dose never does, and it is the reservoir that decides how long the drug stays after you quit taking it. The general rule from the detection-time literature is that chronic use is detectable in urine for about a week after the last dose, and buprenorphine follows it, with the metabolite trailing the parent drug. Searches for whether it can stay in the system for a month or a year refer, in practice, to one situation only: the extended-release injection, covered below, which is designed to.

When the immunoassay and the confirmation disagree

The same single-dose study found that some volunteers screened negative and then positive again on the immunoassay because their urine concentration changed with hydration. That is not a testing error; it is the difference between a screen with a cutoff and a quantitative method. If a result surprises you, the question to ask is which method produced it and at what cutoff.

Does Suboxone show up on a drug test?

Only if the test includes a buprenorphine assay. That sentence answers most of the panel questions people search, and it is worth being precise about which tests do.

The federal five-panel and DOT tests do not include it

The Department of Transportation testing rule, 49 CFR Part 40, lists the drugs its laboratories test and the cutoff for each: marijuana metabolite, cocaine metabolite, codeine and morphine, hydrocodone and hydromorphone, oxycodone and oxymorphone, 6-acetylmorphine, phencyclidine, amphetamine and methamphetamine, MDMA and MDA. Buprenorphine is not on the list. The federal workplace panel it follows does not include it either, which is why the package inserts for instant cups note that SAMHSA has no recommended screening cutoff for buprenorphine: there is no federal test for it to set a cutoff for. A DOT test or a federally regulated workplace test will not detect Suboxone because it does not look.

Ten-panel, twelve-panel and instant cups

Outside the federal programme there is no fixed definition of a ten- or twelve-panel test. Employers, courts and programmes buy panels from laboratories and cup manufacturers, and buprenorphine is an optional strip. When it is included, the common screening cutoff is 10 ng/mL. The only reliable way to know whether a specific ten- or twelve-panel test covers it is to ask what the panel contains; the number tells you how many strips there are, not which ones.

Employment, probation and court testing

Pre-employment and workplace tests outside DOT rules vary by employer, and many use the standard five- or ten-drug panels that omit buprenorphine. Probation, drug court and child-welfare testing very often add it, precisely because these programmes want to know about it, and they tend to use confirmation testing rather than a cup alone. If you are prescribed Suboxone, tell the programme before the first test rather than after a positive; a documented prescription changes what a positive result means.

What it shows up as

Buprenorphine does not register on the opiate strip. Opiate immunoassays are calibrated to morphine and related molecules, and buprenorphine's structure does not trigger them at treatment concentrations. On a panel that includes it, the result appears on its own line, usually labelled BUP, and a confirmation report will list buprenorphine and norbuprenorphine with concentrations. A Suboxone patient who tests positive for opiates has something other than Suboxone in the sample.

If you have a prescription

Regulated testing programmes send confirmed positives to a medical review officer before an employer sees them, and the DOT rule requires the officer to give the employee the chance to present a legitimate medical explanation, with a valid prescription treated as one. Testing that follows the DOT model — most large employers and many courts do — works the same way. Have the prescription and the prescriber's contact details ready, and remember that a legitimate explanation reverses the result; it does not prevent the conversation.

False positives, false negatives, and confirmation

Immunoassay screens are fast and cheap, and they cross-react. For buprenorphine the pattern is well documented, and it runs in both directions.

What can trigger a false positive

In a review of 2,272 urine samples from patients in addiction treatment, 25 screened positive for buprenorphine on a common immunoassay but were negative on mass spectrometry, and codeine, morphine and their metabolites were prevalent in those samples. The same study showed that a therapeutic dose of codeine in a drug-free volunteer produced a positive buprenorphine screen. A separate laboratory analysis found the cross-reactivity only appears when opiate concentrations are very high, above about 2,000 ng/mL. The antipsychotics amisulpride and sulpiride have also produced false positives that mass spectrometry cleared, and a large study mining hospital records found previously unknown cross-reactivities for the buprenorphine assay among others. Raising the screening cutoff from 5 to 10 ng/mL took the assay's specificity to 99.7% in the treatment population, which is one reason cups use 10.

Why a negative can be wrong too

A screen with a 10 ng/mL cutoff misses low concentrations that a confirmation method would find, and dilute urine pushes a sample under the cutoff. In the single-dose study, immunoassay positivity lasted a mean of nine hours against 76 for mass spectrometry. Someone on a low maintenance dose who drinks a great deal of water can screen negative while still taking the medication as prescribed, which matters in a treatment programme where a negative reads as a missed dose or diverted supply.

Confirmation by mass spectrometry

A screening result is not a finding. Laboratory practice, and the DOT rule, require a positive screen to be confirmed by a chromatography-mass-spectrometry method that identifies the molecule itself, and a buprenorphine confirmation reports the drug and the metabolite separately at cutoffs far below the screen. If a result will affect your job, your custody case or your treatment, the question is whether it was confirmed, and by which laboratory.

What a treatment programme's test is really checking

When a Suboxone programme tests your urine, it is rarely asking whether buprenorphine is present. It is asking whether you took your medication, whether the sample is genuinely yours, and what else is there. Modern laboratory panels answer all three, and knowing how makes the results far easier to interpret.

The norbuprenorphine ratio

Because the body makes norbuprenorphine only by metabolising buprenorphine, a genuine sample from someone taking the drug contains both. Drug added directly to a urine cup contains the parent compound and almost no metabolite. A programme that quantified both in 2,275 samples from 168 patients flagged a norbuprenorphine-to-buprenorphine ratio below 0.02 as suspicious; eight samples, 0.35% of the total, from 4.8% of patients, met that definition, and every one contained buprenorphine above 2,000 ng/mL. Commercial laboratory panels for medication-assisted treatment now report this ratio as a line item. The immunoassay alone cannot see any of this, which is why a cup that reads positive is not the whole test.

Naloxone in the sample

The same laboratory panels quantify naloxone. It has a short half-life and low absorption, but it is measurable, and its presence tells the programme the patient took a combination product rather than buprenorphine alone. This matters where a patient is prescribed one and a different product turns up, and it is one more reason treatment-programme testing is a different instrument from an employer's cup.

A negative result when you are prescribed it

An unexpected negative in a programme leads to a conversation, not automatically to discharge. The possibilities include missed doses, very dilute urine, a low dose sitting under the screening cutoff, and diversion, and a confirmation test with concentrations separates most of them. What helps is being straightforward about missed doses before the result arrives, and asking which method and cutoff the programme uses. A programme that cannot tell you is running its testing less carefully than it should.

What changes the timeline

The published ranges assume a healthy adult with a working liver and no interacting medicines. Several things move a person off that assumption, and the label quantifies the largest of them.

Liver function

Buprenorphine is cleared by the liver, and the Suboxone label reports what impairment does to both ingredients. In moderate hepatic impairment, buprenorphine exposure rose 64% and its half-life 35%; in severe impairment, exposure rose 181% and half-life 57%. Naloxone was affected far more — exposure up 218% in moderate and 1,302% in severe impairment, which is why the combination product is not recommended for people with severe liver disease and not recommended for starting treatment in moderate disease. For detection, the practical effect is simple: a damaged liver makes every window longer. Buprenorphine itself can affect liver tests, and programmes monitor them for that reason.

Other medicines that use the same enzyme

The metabolism runs through CYP3A4, so drugs that inhibit that enzyme raise buprenorphine levels and stretch its elimination, and drugs that induce it do the opposite. The label's examples of inhibitors are erythromycin, azole antifungals such as ketoconazole, and protease inhibitors such as ritonavir; its inducers are rifampin, carbamazepine and phenytoin, and among HIV medicines efavirenz, nevirapine and etravirine. Starting or stopping any of these changes both how the medication works and how long it stays measurable, and the label asks prescribers to watch for exactly that.

Kidneys

Only a minority of the dose leaves through urine, and the pharmacokinetic review concluded that dosage does not need significant adjustment in renal impairment. Kidney function changes the concentration in urine more than it changes how long the drug is present in the body.

Age, body fat and metabolism

Buprenorphine is fat-soluble, highly protein-bound and has a large volume of distribution, which is the pharmacological way of saying that it spends much of its time in tissue rather than blood. More tissue to fill, slower metabolism and lower liver blood flow, all more common with age, tend to lengthen the tail. These are tendencies, not numbers, and the individual variation seen in the controlled studies swamps them.

Hydration, dilution and creatinine

Drinking a large volume of water lowers the concentration of everything in urine, including buprenorphine, and can push a sample below a screening cutoff. Laboratories account for it: regulated testing measures creatinine in every sample, treats a value under 20 mg/dL as a signal to check specific gravity, and reports dilute or substituted samples as such rather than as negative. Some programmes report drug concentrations normalised to creatinine for the same reason. Dilution changes the concentration in the cup; it does not change how much drug is in you.

How you take it

Swallowed buprenorphine mostly does not reach the bloodstream, which is why chewing or swallowing the film lowers its effect rather than lengthening it. Misuse by snorting or injecting changes how fast the drug arrives and multiplies the risks, particularly injection of a product that contains naloxone, but it does not materially change how long buprenorphine takes to leave. Whatever the route, the same liver clears the same molecule.

Long-acting buprenorphine changes the answer completely

Everything above describes the film and tablet, which are taken daily and cleared in days. The injectable and transdermal forms are built to release slowly, and their timelines are measured in weeks and months.

Sublocade, the monthly injection

The Sublocade label gives buprenorphine an apparent terminal half-life of 43 to 60 days after injection, because the depot under the skin keeps releasing it. Model simulations in the label show plasma concentrations staying at therapeutic levels for two to five months after the last injection, depending on whether the 100 mg or 300 mg dose was used, and the label states directly that patients who stop after reaching steady state, which takes four to six months, may have detectable plasma and urine levels for twelve months or longer. Anyone asking whether Suboxone can stay in the system for a year is, without knowing it, asking about this product.

Brixadi, weekly and monthly

Brixadi's label reports an apparent terminal half-life of three to five days for the weekly injection (shot) and 19 to 26 days for the monthly, again because of slow release from the injection site rather than slow metabolism. Detection after the last injection runs correspondingly into weeks and months rather than days.

Butrans, the patch

The buprenorphine patch used for pain is a different product at a much lower dose, but it comes up in the same searches. After the patch is removed, the label reports concentrations falling by about half within 10 to 24 hours, then declining with an apparent terminal half-life of around 26 hours, which is why the label warns that monitoring may be needed for at least a day after removal. Detection after stopping runs into days, comparable to the film.

Subutex, Zubsolv and generics

Buprenorphine-only tablets, generic buprenorphine-naloxone films and tablets, and branded products such as Zubsolv all deliver the same molecule by the same route, and the elimination and detection figures on this page apply to them. The differences are in bioavailability and dose equivalence, which change how much reaches the blood, not the rate at which it leaves. The one product-level difference a test can see is naloxone: a buprenorphine-only product leaves none in the urine.

How long Suboxone keeps working: the clock that matters for safety

People also search for how long the blocker lasts, how long it keeps opioids from working, and when withdrawal starts after the last dose. This is the effect clock, and the best evidence for it comes from imaging the receptors directly.

Receptor occupancy fades within days

In a PET imaging study, ten people stabilised on 16 mg a day had their doses withheld and their mu-opioid receptor availability measured at 4, 28, 52 and 76 hours after the last dose. Availability rose from 30% to 54%, 67% and 82% over that period — put the other way, occupancy by buprenorphine fell from about 70% to 46%, 33% and 18%. The same study estimated that roughly 50 to 60% occupancy is needed to suppress withdrawal and to blunt the effect of another opioid. On those numbers, the average person on 16 mg has lost meaningful blockade somewhere between one and two days after the last dose, while a urine test would stay positive for most of a week.

Why the gap between the two clocks is dangerous

The medication protects in two ways: it occupies the receptor so other opioids do less, and it keeps tolerance from falling. Both fade in days. A urine test still reading positive says nothing about either. Someone who stops Suboxone and returns to opioid use a week later is meeting them with reduced tolerance and no blockade, which is the combination that kills people after any period of abstinence. If there is any chance of a return to use, having naloxone in the house is not a comment on anyone's intentions; it is the same logic as a smoke alarm.

The naltrexone question

The elimination clock has one more practical consequence. Starting naltrexone, including the Vivitrol injection, requires an opioid-free interval, and buprenorphine counts as an opioid for that purpose; because it lingers, the interval after buprenorphine is at the longer end, and a naloxone challenge is used to check the receptors are clear before the first dose. Anyone moving between the two medicines is managing exactly the timeline this page describes, and our comparison of naltrexone and Suboxone covers the switch in detail.

Can you get Suboxone out of your system faster?

Not in any way that changes the pharmacology. The honest version of this answer is short, and the marketing version is long.

Water, exercise, detox drinks and kits

Nothing sold as a flush changes the half-life of buprenorphine, which is set by the liver and by how much drug is stored in tissue. Exercise mobilises very little of a fat-soluble drug on the timescale of a test and does nothing to speed the enzyme that clears it. Drinking a great deal of water produces dilute urine, which laboratories are built to recognise, and a dilute or substituted result in a regulated programme is treated as a problem in its own right rather than as a pass.

What actually shortens the window

Time, a working liver, a lower accumulated dose and the absence of interacting medicines. The only lever a person controls is the first one. For someone in treatment, the sensible response to an upcoming test is to keep taking the medication as prescribed and document it; for someone being tested by a programme that has not been told about the prescription, the sensible response is to tell them before the sample, not after.

Pregnancy and breastfeeding

Buprenorphine is used throughout pregnancy for opioid use disorder, and both the timeline and the testing questions come up in prenatal care.

In pregnancy

A small pharmacokinetic study in pregnant women found that peak concentration and total exposure tended to be lower during pregnancy than after delivery, with the time to peak unchanged, and the authors suggested that upward dose adjustment may be needed as pregnancy advances. For detection, the same clearance change points toward a slightly shorter window rather than a longer one. Tests in prenatal care are there to guide treatment, and being on prescribed buprenorphine is the expected finding, not a problem to explain.

Breast milk

The label summarises two studies in 13 women maintained on buprenorphine: the drug and norbuprenorphine were present in milk and in infants' urine at low levels, with the infant receiving about 0.2% of the mother's weight-adjusted dose, and no adverse reactions were seen in the breastfed infants. Naloxone is poorly absorbed by mouth, and the label notes there are no data on the combination in breastfeeding. This is a question for the prescriber and the paediatrician, and the label gives them a reasonable starting point.

After the last dose: detection, withdrawal and detox

The detection window, the withdrawal window and the detox process are three separate things that the word "system" tends to blur. Here is how they relate.

When withdrawal begins

Because buprenorphine leaves slowly and sits tightly on the receptor, withdrawal after stopping it starts later and builds more gradually than after heroin or oxycodone, typically over days rather than hours, and the tail can run for weeks. That is the same slow elimination described on this page seen from the inside. Our guide to the opioid withdrawal timeline covers what those days look like symptom by symptom; this page is about what a laboratory can find, and the two timelines only partly overlap.

Detox, tapering and why cold turkey is not the plan

The label instructs that treatment be discontinued by gradual taper to avoid withdrawal, and every part of the effect clock above is an argument for that: an abrupt stop removes blockade and tolerance together while leaving a detectable but useless residue behind. People searching for how long it takes to detox from Suboxone are usually asking how long a taper takes, and the answer is set by the prescriber and the person, over weeks to months, not by the five-day elimination figure. Nobody has to do it alone, and nobody benefits from doing it fast.

What this page cannot tell you

No clinician has reviewed this page. It is written from the FDA labels, the federal testing regulation, and the peer-reviewed pharmacokinetic and toxicology literature cited at the bottom, and every number above traces to one of those documents. What none of them can do is predict a single person's result: the ranges are population means, the cutoffs vary by laboratory, and the same sample read by a cup and by a mass spectrometer can disagree. If a test result will affect your treatment, your work or a legal matter, the answers you need are the method, the cutoff and whether the result was confirmed, and those come from the laboratory and the programme, not from any page.

Three figures from a single-dose study: 9 hours positive on the immunoassay, 76 hours positive by mass spectrometry
Same dose, same volunteers, three different answers depending on the method. This is why two pages can both be right and still disagree.
Three-column diagram of which tests include buprenorphine: never for DOT and federal panels
The number in ten-panel or twelve-panel tells you how many strips there are, not which. Ask for the list of drugs.
Checklist of what a positive buprenorphine result means: not an opiate result, its own BUP line
A Suboxone patient who tests positive for opiates has something other than Suboxone in the sample.
Warning checklist of causes of false-positive buprenorphine screens: high levels of codeine or morphine
A screening result is not a finding. If it matters, ask whether it was confirmed by mass spectrometry and at what cutoff.

Where this sits in the system of care

Addiction treatment is organised into levels of care, and clinicians choose between them using the ASAM criteria (six dimensions covering withdrawal risk, medical and psychiatric conditions, readiness, relapse risk and, decisively, the environment you return to. Facilities are licensed by the state and many hold additional accreditation from bodies such as the Joint Commission or CARF; that status is worth confirming for any specific programme. Percentages below are our count of how many facilities in the federal directory report offering each level of care.

  1. Detox19.5% of facilitiesmedical withdrawal management, 3–7 daysDetox vs rehab
  2. Residential21.4% of facilitieslive on site, 24-hour staffingInpatient vs outpatient
  3. PHP20–30 structured hours a week, sleep at homePHP vs IOP
  4. IOP9–19 hours a week, usually compatible with workPHP vs IOP
  5. Standard outpatient85.4% of facilities1–8 hours a week, the maintenance levelMutual aid options
“Remaining in treatment for an adequate period of time is critical.”

Programmes for specific groups

Facilities also report dedicated programming, and the coverage is wider than most people expect, worth asking about before assuming a programme will not fit. From our count: 42.7% run programmes for adolescents, 39.2% for veterans, 38% for pregnant and postpartum women, and 25% provide services in Spanish. Medication for opioid use disorder is available at 59.2% (buprenorphine) and 13.7% (methadone).

Cost and coverage vary by level: residential care is the tier insurers scrutinise most and almost always requires prior authorisation before admission. See what your plan covers and how to pay without insurance. Family involvement is a standard part of most programmes, and aftercare planning ( step-down to a lower level, sober living, relapse prevention) should be discussed before admission, not at discharge. If a mental health condition is also present, ask specifically whether the programme is staffed for co-occurring disorders: 69.5% of facilities in the directory report treating them, but that is a self-reported field worth confirming.

Flow diagram of a treatment-programme urine test: validity checks, immunoassay screen, mass-spectrometry quantitation
A programme is rarely asking whether buprenorphine is present. It is asking whether the sample went through a body.
Three figures on urine spiking in one programme: 0.35 percent of 2,275 samples, 4.8 percent of 168 patients
Rare, and detectable by ratio alone. An immunoassay cup cannot see any of this, which is why a positive cup is not the whole test.
Bar chart of increased drug exposure with liver impairment
A damaged liver lengthens every window. The naloxone figures are why the combination product is not recommended in severe liver disease.
Bar chart of mu-opioid receptor occupancy after the last 16 mg buprenorphine dose: about 70 percent at 4 hours, 46 at 28
The protective threshold is roughly 50 to 60 percent. On these figures it is crossed within two days, while a urine test stays positive for most of a week.
Checklist of factors that change how long buprenorphine stays detectable: liver function, medicines sharing CYP3A4
Only one of these is under a person's control, and it is the one laboratories are built to detect.
Bar chart of apparent half-lives of long-acting buprenorphine in days: Brixadi weekly 3 to 5, Brixadi monthly 19 to 26
The depot under the skin, not the liver, sets these clocks. Everything on the page about days becomes weeks and months.
Three figures from the Sublocade label: therapeutic levels for 2 to 5 months after the last injection
Anyone asking whether Suboxone can stay in the system for a year is, without knowing it, asking about this product.
Flow diagram of laboratory handling of dilute urine: creatinine measured, specific gravity checked below 20 mg/dL
Dilution changes the concentration in the cup, not the amount of drug in the person, and regulated laboratories are required to notice.
Timeline of the week after a last daily dose: blockade fades in days one to two, withdrawal builds over days two to five
The four clocks side by side. The dangerous stretch is the first two days, when protection is gone and the test would still say otherwise.
Bar chart of testing performed by US treatment facilities: urine screening 90.4 percent, breath or blood alcohol 64.3
Urine is the default nearly everywhere, and in medication programmes it is close to universal. Our count of the federal directory.
Bar chart of the share of facilities using oral-fluid testing in nine large states
Whether you meet a mouth swab depends heavily on the state, and it is almost always in addition to urine rather than instead of it.
Three figures from the Suboxone label on breastfeeding: 13 women in two studies
The label gives prescribers and paediatricians a starting point. It is a conversation for them, and the numbers are small.
Bar chart of medication for opioid use disorder availability: buprenorphine at 59.2% of facilities, methadone at 13.7%, certified opioid treatment programmes at 12.8%
The four-to-one gap between buprenorphine and methadone availability is a regulatory fact, not a clinical judgement about which works better.
Bar chart of how many US treatment facilities offer each level of care: outpatient 85.4%, residential 21.4%, medical detox 19.5%, hospital inpatient 5.9%
Outpatient care is nearly universal; residential and detox are the scarce tiers. That scarcity is part of why they cost what they do and why waits exist.
Checklist of six questions to ask a treatment facility about network status, prior authorisation, all-in cost, medication availability, aftercare and accreditation
How plainly a programme answers these is itself information about how it operates.
Table showing when to call 911, 988 or the SAMHSA National Helpline for overdose, immediate danger, suicidal thoughts, severe distress and treatment questions
All three are free and staffed around the clock. 988 is the Suicide & Crisis Lifeline; the SAMHSA National Helpline is 1-800-662-4357.

Common questions

How long after taking Suboxone will it show up in a urine test?

Within hours. In a controlled single-dose study, samples were positive on the immunoassay within the first few hours, the ratio of metabolite to parent drug crossed one at about seven hours, and mass spectrometry found the drug for a mean of 76 hours after a very small dose. Someone on daily treatment is continuously positive; the question for them is not when it appears but how long it stays after stopping, which is about a week.

Does Suboxone show up as an opiate on a drug test?

No. Opiate immunoassays are calibrated to morphine and related molecules and do not react to buprenorphine at treatment concentrations. On a panel that includes buprenorphine, it appears on its own line, usually marked BUP, and a confirmation report lists buprenorphine and norbuprenorphine separately. A Suboxone patient who tests positive for opiates has something other than Suboxone in the sample.

How long does 8 mg of Suboxone stay in your system?

The dose does not change the half-life of 24 to 42 hours; it changes where the curve starts. A single 8 mg dose is detectable in urine for several days by confirmation testing and for a shorter period on a screening cup. After daily 8 mg dosing for months, the accumulated drug takes about a week to fall below typical urine cutoffs, with the metabolite norbuprenorphine detectable at the tail end.

How long does one-time use or half a strip stay in your system?

A single small dose is the best-studied case: after 0.4 mg, mass spectrometry found buprenorphine for a mean of 76 hours, with a range of 23 to 96, and the immunoassay for a mean of only nine hours. Half of a 2 mg or 8 mg film is a larger dose and sits above the cutoff longer, but without the tissue reservoir that daily use builds, so expect days rather than a week.

Does Suboxone show up on a DOT drug test?

No. The DOT rule at 49 CFR Part 40 lists the drugs tested — marijuana, cocaine, codeine and morphine, hydrocodone, hydromorphone, oxycodone, oxymorphone, 6-acetylmorphine, PCP, amphetamine, methamphetamine, MDMA and MDA, and buprenorphine is not among them. The federal workplace panel the DOT follows does not include it either, which is why instant-cup inserts note that SAMHSA has no recommended cutoff for it.

Does Suboxone show up on a 10-panel or 12-panel drug test?

Only if the panel includes a buprenorphine strip, and there is no standard definition of what a ten- or twelve-panel test contains outside the federal programme. Some include buprenorphine, commonly at a 10 ng/mL screening cutoff, and many do not. The number tells you how many drugs are tested, not which; ask for the list.

Will Suboxone show up on a hair follicle test?

Yes, if the test looks for it. Controlled studies found buprenorphine and its metabolite in the hair segments corresponding to the period of treatment, at roughly a centimetre of hair per month, so a standard 3 cm sample covers about three months. Hair cannot reliably show how much someone took, and one participant in the controlled study had no detectable drug in any segment.

How long does Sublocade stay in your system?

Months, by design. The label gives an apparent half-life of 43 to 60 days, therapeutic blood levels for two to five months after the last injection depending on the dose, and detectable plasma and urine levels for twelve months or longer in people who stop after reaching steady state. Brixadi runs to weeks for the weekly formulation and months for the monthly one.

Will Suboxone make me fail a drug test?

Only a test that includes a buprenorphine assay can detect it, and a confirmed positive with a valid prescription is a legitimate medical explanation, not a failed test. In regulated programmes a medical review officer verifies the result before an employer sees it. What does fail is the opiate strip: buprenorphine does not trigger it, so a Suboxone patient positive for opiates has something else in the sample. Tell the tester about the prescription before the sample, and keep the documentation.

Can you drive with Suboxone in your system?

Once stable on a steady dose, most people drive, and the labels do not prohibit it. They do caution against driving or operating hazardous machinery until you are reasonably certain the medication does not affect you, which mainly means the first days of treatment and any dose change, and they warn that combining it with alcohol, benzodiazepines or other sedatives is dangerous. Being detectable in urine is not the same as being impaired; impairment is what matters at the wheel.

Can I check myself with an at-home buprenorphine test?

Home strips sold online and at pharmacies such as Walgreens or CVS are the same immunoassay used in instant cups, usually with a 10 ng/mL cutoff. They will show whether buprenorphine is above that level in your urine at that moment, which is useful for the simple question and useless for the hard ones: they cannot see the metabolite ratio, cannot distinguish dilute urine from a genuine negative, and can cross-react with high levels of codeine or morphine. A laboratory confirmation answers what a strip cannot.

Sources

Compare levels of care

Check what your plan covers

How this page was made

Who wrote it:
the Treatment Compass editorial team : researchers and writers, not clinicians. No doctor has reviewed this page, and we do not claim otherwise. What that means in practice: we report what public clinical sources say and show you where to read them, rather than offering a clinical opinion of our own.
Checked against:
25 primary sources listed above: federal agency material and published clinical criteria. Where a figure varies by state, plan or facility, we say so instead of publishing a number that looks authoritative and is not.
Original analysis:
the facility proportions on this page are our own count of SAMHSA’s public directory. The full method is documented , including what we count, what we deliberately do not publish, and an error the approach caught. You can repeat the pull and check the numbers.
Last reviewed:
. This date changes when the content is actually re-checked, not automatically on every visit.
What this page is not:
a medical recommendation, a diagnosis, or a referral. Decisions about levels of care and medication belong with a clinician who knows your history. We do not operate facilities, take placement fees, or receive payment for sending anyone anywhere.

Related on this site

More guides

Weighing levels of care? See PHP vs IOP and what your insurance covers.

This page is information, not medical or legal advice. Laws on commitment and treatment differ by state. If you are in crisis, call or text 988 in the US, or reach the SAMHSA National Helpline at 1-800-662-4357 — free, confidential, 24/7.